NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Contract Research Orgs » MPI Research  1    
found files: 4
MPI Research »23/12/2007 [Company watch]
MPI & China Medicilon announce JV

MPI Research and Shanghai Medicilon are pleased to announce a new joint venture to form Medicilon-MPI Preclinical Research (Shanghai) LLC. Located initially at the Zhangjiang Hi-Tech Park in Shanghai, China, the company will open a 50,000 ft(2) preclinical testing facility in the Chuansha Economic Park in early 2008. This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies worldwide....   more»


MPI Research »27/01/2008 [Company watch]
MPI Research ties-up with Shanghai Medicilon

MPI Research has tied up with Shanghai Medicilon to form Medicilon-MPI Preclinical Research. Located at the Zhangjiang Hi-Tech Park in Shanghai, China, the company will open a 50,000 ft 2 preclinical testing facility in the Chuansha Economic Park in early 2008. This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies worldwide. A prepared company release said, “With the joint venture, customers of both parent companies will have the advantage of conducting research at the Shanghai site for preclinical development, with potential for worldwide release. Current and future customers of Medicilon and MPI Research will now have access to a broader range of both GLP and non- GLP preclinical services. By 2009, the new company will be fully operational, in terms of conducting FDA/IND enabling studies, offering additional preclinical support services, submitting INDs and NDAs, and will have AAALAC accreditation.” "With one fourth of the world's population, China is an important force in shaping the global pharmaceutical and biotechnology markets," says MPI Research's Chairman and CEO, William U. Parfet. "We have carefully looked for more than three years to find a CRO partner that shares our values and commitment to excellence, and we have finally found one in Shanghai Medicilon. We look forward to forging a future together as a worldwide leader of preclinical research services." Dr. Chun-Lin Chen, co-founder of Medicilon, Inc. as well as Shanghai Medicilon will serve as the CEO of Medicilon-MPI Preclinical Research. Dr Chen is a highly published thoughtleader in the pharmaceutical industry with extensive experience in academia, pharmaceutical, and regulatory evaluation. Dr. Chen received his PhD from Oklahoma State University, and completed post-doctoral training in the United States. Dr. Chen has held numerous leadership positions in professional scientific trade organizations in China as well as other parts of the world....   more»


MPI Research »17/10/2008 [Company watch]
China gets a new preclinical research facility

China-based Medicilon and Michigan, US-based MPI Preclinical Research have jointly opened a new preclinical research facility in Shanghai, China. The two parent companies are equally represented in this new joint venture. The 50,000 square foot building is located in the Chuansha Economic Park in Shanghai. This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies worldwide. Dr Chun-Lin Chen, co-founder of Shanghai Medicilon, serves as the CEO of the joint venture, Medicilon/MPI Preclinical Research. Mr William U Parfet, Chairman and CEO of MPI Research, serves as the Chairman of the Board of Directors for the JV. Mr William Harrison, President and COO of MPI Research; Dr Jintao Zhang, CEO of Shanghai Medicilon; and Dr Chen are also serve as directors. As per the company release, Medicilon/MPI Preclinical Research provides global pharmaceutical and biotechnology companies with high quality preclinical drug discovery and development studies in an Asian facility that meets worldwide regulatory standards. The new company offers the advantage of conducting research at the Shanghai site for preclinical development, with potential for worldwide release. Customers will now have access to a broader range of both GLP and non-GLP preclinical services in China, such as toxicology, ADME, and pharmacodynamics. In 2009, the joint venture will be fully operational in terms of conducting US GLP FDA/IND enabling studies, and will receive AAALAC accreditation. According to the joint venture’s CSO, Dr Stephen Porter, with the addition of this important new preclinical development resource in China, Medicilon/MPI Preclinical Research Shanghai would usher in a new era of pharmaceutical development and would create the beginning of the 'second silk road' for China. MPI Research and Shanghai Medicilon will remain independent parent companies to the newly formed joint venture....   more»


MPI Research »26/10/2009 [Company watch]
Medicilon/MPI Preclinical Research-Shanghai Receives AAALAC Certification

Medicilon/MPI Preclinical Research-Shanghai has been recognized as an accredited International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. This accreditation further underscores the company’s commitment to quality research. The AAALAC initiative was led by Lijie Fu, PhD, Executive Vice President of Operations, a national returnee with substantial industry, scientific and CRO experience....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.